出典:Wikipedia
出典:『Wikipedia』 (2011/05/01 00:05 UTC 版)
TM38837 is a new small molecule inverse agonist/antagonist of the CB1 receptor Cannabinoid receptor. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma. The company has announced phase I clinical trials.